| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | GTBP; HSAP; p160; GTMBP; HNPCC5 |
| Entrez GeneID | 2956 |
| clone | 7D9H5 |
| WB Predicted band size | 152.8kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human MSH6 (AA: 374-540) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇与MSH6抗体相关的文献及其简要摘要：
---
1. **文献名称**: *Immunohistochemistry for MSH6 in the identification of Lynch syndrome*
**作者**: Shia J et al.
**摘要**: 本研究评估了MSH6抗体在免疫组化(IHC)中对林奇综合征筛查的临床价值。研究发现，MSH6蛋白表达缺失与基因突变高度相关，可作为遗传性结直肠癌和子宫内膜癌的辅助诊断标志物，但需结合其他错配修复蛋白(如MSH2)结果综合分析。
---
2. **文献名称**: *Comparative analysis of MSH6 antibody clones in colorectal cancer diagnostics*
**作者**: Kåbjörn-Gustafsson C et al.
**摘要**: 通过比较不同克隆的MSH6抗体(如EPR3945和44MSH6)在结直肠癌组织中的染色性能，发现EPR3945具有更高的敏感性和特异性，强调了抗体选择对准确评估错配修复缺陷(dMMR)的重要性。
---
3. **文献名称**: *MSH6 mutations and antibody-based screening in hereditary cancer syndromes*
**作者**: Hampel H et al.
**摘要**: 探讨了MSH6基因突变与抗体检测在遗传性癌症家系中的应用，指出MSH6抗体免疫组化可作为初步筛查工具，但其阴性预测值较低，需通过基因测序进一步验证突变。
---
如需更多文献或扩展方向(如技术优化或疾病关联研究)，可进一步说明需求。
The MSH6 antibody is a crucial tool in studying the DNA mismatch repair (MMR) system, which corrects replication errors to maintain genomic stability. MSH6. a protein encoded by the *MSH6* gene, forms a heterodimer with MSH2 (MutS homolog 2) to recognize mismatched nucleotides during DNA replication. This complex initiates repair by recruiting other MMR proteins, such as MLH1 and PMS2. Defects in MSH6 disrupt MMR, leading to microsatellite instability (MSI), a hallmark of Lynch syndrome (hereditary nonpolyposis colorectal cancer) and a subset of sporadic cancers, including endometrial, gastric, and colorectal cancers.
Antibodies targeting MSH6 are widely used in immunohistochemistry (IHC) to assess MMR protein expression in tumor tissues. Loss of MSH6 staining, often alongside retained MSH2. helps diagnose Lynch syndrome or identify MSI-high tumors, guiding clinical management and genetic counseling. Research applications include studying MMR mechanisms, evaluating therapeutic responses in MSI-related cancers, and exploring associations with immunotherapy efficacy, as MSI-high tumors often exhibit heightened immune checkpoint inhibitor sensitivity.
MSH6 mutations or epigenetic silencing can cause functional impairment, making the antibody vital for both diagnostic and research contexts. Its role in precision oncology underscores its importance in personalized cancer care and hereditary cancer risk assessment.
×
